Michael Wyand
Algemeen Directeur bij Oxeia Biopharmaceuticals, Inc.
Profiel
Dr. Michael Wyand is a Chief Executive Officer & Director at Oxeia Biopharmaceuticals, Inc. and a Chief Executive Officer & Director at Onebiopharma, Inc. He is on the Board of Directors at Oxeia Biopharmaceuticals, Inc. and Onebiopharma, Inc. Dr. Wyand was previously employed as a SVP-Clinical, Regulatory & Manufacturing by Zalicus, Inc. and a President & Chief Operating Officer by EPIRUS Biopharmaceuticals, Inc. He received his undergraduate degree from the University of Connecticut and a doctorate degree from Purdue University.
Actieve functies van Michael Wyand
| Bedrijven | Functie | Begin |
|---|---|---|
Oxeia Biopharmaceuticals, Inc.
 Oxeia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oxeia Biopharmaceuticals, Inc. is a clinical-stage biotech company, which develops new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Its two indications are for (i) mild traumatic brain injury (?mTB?) known as concussion, and (ii) the cognitive decline, lethargy and ?brain-fog? associated with Covid-19 infection, known as Covid Longhauler syndrome (?Long Covid?). The company was founded in 2014 by Vishal Bansal, Amit Dilip Munshi & Kartik Kiran Shah and is headquartered in Boston, MA. | Algemeen Directeur | 06-09-2017 |
Onebiopharma, Inc.
 Onebiopharma, Inc. Medical/Nursing ServicesHealth Services Onebiopharma, Inc. provides health care services. The company is headquartered in Boston, MA. | Algemeen Directeur | - |
Eerdere bekende functies van Michael Wyand
| Bedrijven | Functie | Einde |
|---|---|---|
| EPIRUS BIOPHARMACEUTICALS, INC. | President | 30-06-2016 |
Zalicus, Inc.
 Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Michael Wyand
| Purdue University | Doctorate Degree |
| University of Connecticut | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| EPIRUS BIOPHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Oxeia Biopharmaceuticals, Inc.
Oxeia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oxeia Biopharmaceuticals, Inc. is a clinical-stage biotech company, which develops new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Its two indications are for (i) mild traumatic brain injury (?mTB?) known as concussion, and (ii) the cognitive decline, lethargy and ?brain-fog? associated with Covid-19 infection, known as Covid Longhauler syndrome (?Long Covid?). The company was founded in 2014 by Vishal Bansal, Amit Dilip Munshi & Kartik Kiran Shah and is headquartered in Boston, MA. | Health Technology |
Onebiopharma, Inc.
Onebiopharma, Inc. Medical/Nursing ServicesHealth Services Onebiopharma, Inc. provides health care services. The company is headquartered in Boston, MA. | Health Services |
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |